UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 8-K
___________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 20, 2020
___________________________________________
CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)
___________________________________________
|
|
|
|
|
|
|
|
|
Florida
|
1-13165
|
59-2417093
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (770) 419-3355
_________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange
on which registered
|
|
Common Stock, $0.01 par value
|
CRY
|
NYSE
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
Section 5
|
Corporate Governance and Management
|
|
|
|
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
At CryoLife, Inc.’s (the “Company” or “CryoLife”) 2020 Annual Meeting of Stockholders held on May 20, 2020 (the “Annual Meeting”), CryoLife’s stockholders elected each individual that was nominated for election as director of the Company to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also (i) approved, by non-binding vote, the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, (ii) approved the new CryoLife, Inc. Equity and Cash Incentive Plan with funding of 2,675,000 shares, and (iii) ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2020.
The final results of the voting on each matter of business at the 2020 Annual Meeting are as follows:
Election of Directors
|
|
|
|
|
|
Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Thomas F. Ackerman
|
27,818,416
|
388,438
|
3,198,869
|
|
Daniel J. Bevevino
|
27,700,716
|
506,138
|
3,198,869
|
|
Marna P. Borgstrom
|
28,117,808
|
89,046
|
3,198,869
|
|
James W. Bullock
|
27,695,918
|
510,936
|
3,198,869
|
|
Jeffrey H. Burbank
|
27,696,171
|
510,683
|
3,198,869
|
|
J. Patrick Mackin
|
27,587,727
|
619,127
|
3,198,869
|
|
Ronald D. McCall, Esq.
|
23,527,589
|
4,679,265
|
3,198,869
|
|
Harvey Morgan
|
27,862,655
|
344,199
|
3,198,869
|
|
Jon W. Salveson
|
23,815,777
|
4,391,077
|
3,198,869
|
Approval, by non-binding vote of the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.
|
|
|
|
|
|
Votes For
|
Votes Against
|
Votes Abstain
|
Broker Non-Votes
|
|
27,529,863
|
476,504
|
200,487
|
3,198,869
|
Approval of the new CryoLife, Inc. Equity and Cash Incentive Plan, with funding of 2,675,000 shares.
|
|
|
|
|
|
Votes For
|
Votes Against
|
Votes Abstain
|
Broker Non-Votes
|
|
27,109,999
|
912,110
|
184,745
|
3,198,869
|
Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2020.
|
|
|
|
|
|
Votes For
|
Votes Against
|
Votes Abstain
|
|
|
31,345,874
|
43,818
|
16,031
|
|